Literature DB >> 14701896

Optimal strategies for identifying patients with myocardial infarction in general practice.

Peter T Donnan1, Hamish T Dougall, Frank M Sullivan.   

Abstract

BACKGROUND: In order to provide evidence-based secondary prevention of coronary heart disease (CHD) in general practice, eligible patients need to be identified. The optimal strategy is one in which all appropriate patients are identified with the least effort.
OBJECTIVE: The purpose of the study was to determine the optimal strategy to identify subjects with a myocardial infarction (MI) from general practice records using different search criteria.
METHODS: The study was a cross-sectional survey of 10 general practices in Tayside, Scotland. A random sample of all subjects aged over 35 (n = 5061) and registered with the general practices was obtained. The main outcome measures were sensitivity, specificity, positive predictive value (PPV) and yield (the number of records that need to be examined to detect a "true case").
RESULTS: Of the sample of 5061, 207 (4.1%) were defined to have had a "gold standard" MI. A Read code for ischaemic heart disease (IHD) had the highest sensitivity (95%) but with a poor PPV (52%). All searches had high specificities. The addition of a record of hospitalization for MI to the Read code for MI gave 100% sensitivity and high yield (1 in 1.11). In situations where the Read coding is of poor quality, the alternative search strategy of a hospital record of MI or receiving aspirin or nitrates was optimum.
CONCLUSIONS: Patients who had experienced an MI can be easily identified from a combination of a Read code for MI and a record of hospitalization for an MI giving 100% sensitivity and specificity with a yield of 1 in 1.11.

Entities:  

Mesh:

Year:  2003        PMID: 14701896     DOI: 10.1093/fampra/cmg614

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  7 in total

1.  Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials.

Authors:  Li Wei; Shah Ebrahim; Christopher Bartlett; Peter D Davey; Frank M Sullivan; Thomas M MacDonald
Journal:  BMJ       Date:  2005-03-24

2.  Variations in cardiovascular disease under-diagnosis in England: national cross-sectional spatial analysis.

Authors:  Michael Soljak; Edgar Samarasundera; Tejal Indulkar; Hannah Walford; Azeem Majeed
Journal:  BMC Cardiovasc Disord       Date:  2011-03-17       Impact factor: 2.298

3.  A retrospective cohort study assessing patient characteristics and the incidence of cardiovascular disease using linked routine primary and secondary care data.

Authors:  Rupert A Payne; Gary A Abel; Colin R Simpson
Journal:  BMJ Open       Date:  2012-04-13       Impact factor: 2.692

4.  Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE).

Authors:  Peter T Donnan; David McLernon; Douglas Steinke; Stephen Ryder; Paul Roderick; Frank M Sullivan; William Rosenberg; John F Dillon
Journal:  BMC Health Serv Res       Date:  2007-04-16       Impact factor: 2.655

5.  Impact on mortality following first acute myocardial infarction of distance between home and hospital: cohort study.

Authors:  L Wei; C C Lang; F M Sullivan; P Boyle; J Wang; S D Pringle; T M MacDonald
Journal:  Heart       Date:  2007-11-05       Impact factor: 5.994

6.  Identification of major cardiovascular events in patients with diabetes using primary care data.

Authors:  Koen Bernardus Pouwels; Jaco Voorham; Eelko Hak; Petra Denig
Journal:  BMC Health Serv Res       Date:  2016-04-02       Impact factor: 2.655

Review 7.  Validity of Acute Cardiovascular Outcome Diagnoses Recorded in European Electronic Health Records: A Systematic Review.

Authors:  Jennifer Davidson; Amitava Banerjee; Rutendo Muzambi; Liam Smeeth; Charlotte Warren-Gash
Journal:  Clin Epidemiol       Date:  2020-10-14       Impact factor: 4.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.